{"id":"W4282939251","doi":"10.1158/1538-7445.am2022-ct537","title":"Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Surgery; Internal medicine; Randomization; Discontinuation; Intention-to-treat analysis; Hazard ratio; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001610107,0.001978103,0.002359051,0.0004350653,0.0004203179,0.0007883193,0.0007602383,0.001558612,0.009285302],"category_scores_gemma":[0.001074465,0.0005142821,0.001217268,0.0004196629,0.001215735,0.0008846359,0.0003294761,0.002546743,0.001411628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006878607,"about_ca_system_score_gemma":0.001800486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007359381,"about_ca_topic_score_gemma":0.001914765,"domain_scores_codex":[0.9994623,0.0002739669,0.00003425228,0.0001142072,0.00004461984,0.00007072536],"domain_scores_gemma":[0.9993224,0.0001099796,0.0001588629,0.0000513799,0.00005535406,0.0003019707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9688848,0.006468116,0.0006158696,0.0004982772,0.0005835829,0.00005840556,0.00003554619,0.000324336,0.008169042,0.00009718793,0.001932177,0.01233263],"study_design_scores_gemma":[0.9621817,0.03576017,0.0008933566,0.00001265899,0.0001615491,0.00002609333,0.000005494302,0.0002183283,0.0003603475,0.00004990999,0.0003230227,0.000007302692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980086,0.00440314,0.0008359977,0.001026985,0.0005029511,0.007024298,0.003098359,0.0003448389,0.002677345],"genre_scores_gemma":[0.9778827,0.002205079,0.002186061,0.001556327,0.0004690146,0.00755555,0.003712832,0.00004940604,0.00438299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009285302,"threshold_uncertainty_score":0.03106242,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08475048191245492,"score_gpt":0.4207714481141023,"score_spread":0.3360209662016473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}